Skip to content

From target identification to lead selection

A transformative platform that facilitates the advancement of next-generation immunotherapies

To develop effective antibody-based therapeutic strategies for solid tumors, we must confront the challenges inherent in outdated discovery processes. Emglev represents a fusion of state-of-the-art technologies, providing a transformative platform for advancing next-generation immunotherapies tailored to solid tumor treatment.
This innovative amalgamation of techniques promises to revolutionize cancer treatment by introducing novel, highly effective approaches, uniquely positioned to tackle the complex challenges presented by solid tumor malignancies. Next generation immunotherapies will be at the forefront of this revolution.
Existing platforms

Target

Lack of validated target ;
Undruggable validated targets.

sELECTION

Diversity ;
Immunological bias.

Screening

Lack of functionnal screening methods ;
In vitro and In vivo validation.

Engineering

Risk, time and costs.

Therapeutic candidates

mAB : large molecular size CAR-T cell therapies (based on scFv) : oligomerization.
Time from selection to engineering: 6 to 12 months
Emglev platform

E-LIB

2 humanized single domain libraries ;
Fully synthetic sd-Ab ;
Target identification (GPCR…) from patient samples.

E-SCREEN

Functional screening ;
in vitro & in vivo validation.

E-ENGINE

Modulable ;
Specificity.

E-BODY

Small size ;
Robust ;
Low off-target ;
No aggregation ;
Multi-format including CAR, bispecific and ADC-based therapies.
Time to select a candidate : 2 months

EMGLEV Therapeutics

A unique proprietary platform and deep expertise combining all the advantages to provide unique targets and lead candidates

E-LIB

Unique fully synthetic sdAb libraries.
  • Patented ;
  • Target identification from patient samples ;
  • Worldwide recognition.

E-ENGINE

All therapeutic formats

  • CAR
  • Bispecific
  • ADC

E-BODY

Lead candidate against any target.

  • Low off-target.
  • Robust ;
  • Small size ;

E-SCREEN

20 Years of know-how

  • In vitro and in vivo validation
  • Functional screening

E-LIB

Unique fully synthetic sdAb libraries.
Patented ;
Target identification from patient samples ;
Worldwide recognition.

E-ENGINE

All therapeutic formats

CAR
Bispecific
ADC

Low off-target.
Robust ;
Small size ;

Lead candidate against any target.

E-BODY


In vitro and in vivo validation
Functional screening
20 Years of know-how


E-SCREEN

Publications

"NaLi-H1: A universal synthetic library of humanized nanobodies providing highly functional antibodies and intrabodies" - ELIFE
Sandrine Moutel, Nicolas Bery, Virginie Bernard, Laura Keller, Emilie Lemesre, Ario de Marco, Laetitia Ligat, Jean-Christophe Rain, Gilles Favre, Aurélien Olichon, Franck Perez (2016 - July 19)
Read
"Nanobodies against surface biomarkers enable the analysis of tumor genetic heterogeneity in uveal melanoma patient-derived xenografts" - PIGMENT CELL & MELANOMA RESEARCH
Ronan Crépin, David Gentien, Angeline Duché, Audrey Rapinat, Cecile Reyes, Fariba Némati, Gérald Massonnet, Didier Decaudin, Selma Djender, Sandrine Moutel, Klervi Desrumeaux, Nathalie Cassoux, Sophie Piperno-Neumann, Sebastian Amigorena, Franck Perez, Sergio Roman-Roman, Ario de Marco  (2017 May 01st)
Read
"Whole-cell biopanning with a synthetic phage display library of nanobodies enabled the recovery of follicle-stimulating hormone receptor inhibitors" - BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
Ronan Crepin, Gianluca Veggiani, Selma Djender, Anne Beugnet, François Planeix, Christophe Pichon, Sandrine Moutel, Sebastian Amigorena, Franck Perez, Nicolae Ghinea, Ario de Marco  (2017 December 01st)
Read
"Selection and Use of Intracellular Antibodies" - ANTIBODY ENGINEERING
Sandrine Moutel, Clément Nizak, Franck Perez (2018 January 01st)
Read
"Surface LSP-1 Is a Phenotypic Marker Distinguishing Human Classical versus Monocyte-Derived Dendritic" - Cells ISCIENCE
Sandrine Moutel, Anne Beugnet, Aurélie Schneider, Bérangère Lombard, Damarys Loew, Sebastian Amigorena, Franck Perez, Elodie Segura (2020 April 01st)
Read
"Novel FGFR4-Targeting Single-Domain Antibodies for Multiple Targeted Therapies against Rhabdomyosarcoma" -  CANCERS
Nagjie Alijaj, Sandrine Moutel, Zelia L. Gouveia, Maxim Gray, Maurizio Roveri, Dzhangar Dzhumashev, Florian Weber, Gianmarco Meier, Paola Luciani, Jochen K. Rössler, Beat W. Schäfer, Franck Perez, Michele Bernasconi (2020 November 10)
Read
Previous slide
Next slide

Emglev Therapeutics is a forward-looking company specializing in the exploration and development of revolutionary immunotherapies using next-generation synthetic single-domain antibodies.

© Copyright 2023 Emglev Therapeutics. All rights reserved